Patents Examined by Kendra D. Carter
  • Patent number: 10413535
    Abstract: The invention relates to antagonists of integrin ?4 and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for treating ocular inflammatory conditions, such as dry eye disease, non-infectious uveitis (e.g., anterior, intermediate, posterior, pan-uveitis), non-infectious conjunctivitis, iritis, or scleritis in animals, and particularly mammals, including humans.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: September 17, 2019
    Assignee: AXEROVISION, INC.
    Inventor: Achim H. Krauss
  • Patent number: 10370335
    Abstract: The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I wherein R1, R2, R3, R5, R6 and R7 are independently X3R where R is selected from the group consisting of H, halo; optionally substituted saccharide, aliphatic, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; —P(O)(ORa)(ORb) and —NRaRb, where Ra and Rb are independently H, optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; X1, X2 and X3 are independently —C(O)O—, —OC(O)—, —C(O)NH—, —NHC(O)—, —OC(O)NH—, —NHC(O)O—, —OS(O)y—, —S(O)y—, —O—, —NHC(O)—, —NHC(O)O—, —S(O)2NH—, a bond or absent; where y is an integer from 0 to 3; and R4 and R8 are independently H, (?O); hydroxy; or optionally substituted saccharide, aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or —P(O)(ORa)(ORb) or —NRaRb, where Ra and Rb are independently H, or optionally substituted aliphatic, cycloalkyl or heterocycloalkyl, aryl or heteroaryl; or a prodrug
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: August 6, 2019
    Assignee: Naturon, Inc.
    Inventors: Neal S. Bricker, Stewart Shankel, Christopher D. Cain, Mark A. Mitchnick, Michael Schmertzler
  • Patent number: 10369117
    Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: August 6, 2019
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 10342768
    Abstract: The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: July 9, 2019
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov, Rodolphe Hajj
  • Patent number: 10342784
    Abstract: The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: July 9, 2019
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov, Rodolphe Hajj
  • Patent number: 10314816
    Abstract: Described herein are antimicrobial compounds identified via a high-throughput inhibitor screen of the in vitro activity of MipZ, which is an ATPase that regulates division site placement in Caulobacter crescentus. The compounds and their analogs are active against bacterial membranes and thus represent a novel class of antimicrobial compounds. The antimicrobial compounds are effective against both actively growing bacterial cells as well as bacterial cells in the stationary phase. The antimicrobial compounds are also effective against bacteria in biofilms.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: June 11, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Douglas Benjamin Weibel, Ye Jin Eun, Marie Hazel Foss, Katherine Ann Hurley
  • Patent number: 10301265
    Abstract: The invention provides potent quinolinol-based BoNT/A small-molecule inhibitors of botulinum neurotoxins, in particular of Clostridium botulinum serotype A neurotoxins. The invention also provides methods of using these small-molecule inhibitors to inhibit infections by Clostridium botulinum, as well as, methods of preventing infections by Clostridium botulinum through materials that may be ingested.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: May 28, 2019
    Inventors: Virginia I. Roxas-Duncan, Leonard A. Smith, Nizamettin Gul, John H. Cardellina, II, Rebecca C. Vieira, Susan M. Ensel, David C. H. Yang, Istvan J. Enyedy, Sivanesan Dakshanamurthy, Salimuddin Shah
  • Patent number: 10300065
    Abstract: The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: May 28, 2019
    Assignee: ASTRAZENECA AB
    Inventors: Lars Magnus Andersson, Tomas Lars-Gunnar Andersson, Olof Fredrik Bengtsson, Hans Peter Held, Garnet Edward Howells, Eva Christina Jensen, Robert Storey
  • Patent number: 10292969
    Abstract: The present invention relates to a composition for prevention or treatment of bronchial asthma comprising a PKR inhibitor as an active ingredient. The PKR inhibitor and derivatives thereof according to the present invention can be used as a pharmaceutical for prevention, amelioration or treatment of bronchial asthma and as a supplementary health food because the PKR inhibitor and derivatives thereof reduce the total counts of inflammatory cells, eosinophils, neutrophils and lymphocytes in bronchoalveolar lavage fluid of neutrophilic severe asthma-induced mice, reduce airway inflammation and airway hyper-responsiveness, and reduce inflammatory mediators.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: May 21, 2019
    Assignee: Undustrial Cooperation Foundation Chonbuk National University
    Inventors: Yong Chul Lee, So Ri Kim
  • Patent number: 10278946
    Abstract: The present invention relates to a stable liquid formulation of cabazitaxel. The formulation comprises cabazitaxel and at least one solubilizer. Typically, formulations are in the form of ready-to-use solutions or concentrates.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: May 7, 2019
    Assignee: EMCURE PHARMACEUTICALS LIMITED
    Inventors: Hiren Pravinbhai Patel, Haresh Ishwarbhai Patel, Arpan Suresh Chudasama, Neha Manubhai Patel, Deepak Pragjibhai Gondaliya, Mukund Keshav Gurjar, Samit Satish Mehta
  • Patent number: 10233197
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: March 19, 2019
    Assignee: TECHFIELDS PHARMA CO., LTD.
    Inventor: Chongxi Yu
  • Patent number: 10213432
    Abstract: The present invention relates to a dosage regimen for a phosphatidylinositol 3-kinase (PI3K) inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a dosage regimen for the treatment of patients suffering from a proliferative disease, such as, for example, cancer, with a phosphatidylinositol 3-kinase (PI3K) inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: February 26, 2019
    Assignee: NOVARTIS AG
    Inventors: Samit Hirawat, Cristian Massacesi
  • Patent number: 10196402
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 5, 2019
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Patent number: 10189856
    Abstract: The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: January 29, 2019
    Assignee: Adverio Pharma GMBH
    Inventors: Claudia Hirth-Dietrich, Peter Sandner, Johannes-Peter Stasch, Andreas Knorr, Georges Von Degenfeld, Michael Hahn, Markus Follmann
  • Patent number: 10131657
    Abstract: The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: November 20, 2018
    Assignee: AbbVie Inc.
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • Patent number: 10131643
    Abstract: The invention relates to a tizoxanide carbamate compound of Formula I and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and their pharmaceutical use.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: November 20, 2018
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Xingzhou Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Xinbo Zhou, Yunde Xie, Xiaokui Wang, Lili Wang, Wei Chen, Fei Xie
  • Patent number: 10111429
    Abstract: Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: October 30, 2018
    Assignee: BEDOUKIAN RESEARCH, INC.
    Inventor: Robert H. Bedoukian
  • Patent number: 10085975
    Abstract: Provided herein are novel and selective high affinity ?3?4 nicotinic acetycholine receptor ligands and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, drug addiction or pain using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of selectively antagonizing receptors such as, for example, the ?3?4 nicotinic acetycholine receptor using the compounds and compositions disclosed herein.
    Type: Grant
    Filed: April 23, 2017
    Date of Patent: October 2, 2018
    Assignee: Astraea Therapeutics, Inc.
    Inventors: Nurulain Zaveri, Faming Jiang, Lawrence Toll
  • Patent number: 10059663
    Abstract: Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: August 28, 2018
    Assignee: KYOTO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Hiroaki Shirahase, Kenji Takahashi, Yoshimichi Shoji, Shigemitsu Takeda
  • Patent number: 10053431
    Abstract: Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: August 21, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shaoqing Chen, Andrew F. Donnell, Robert Francis Kester, Kang Le, Yan Lou, Christophe Michoud, Stacy Remiszewski, Kenneth C. Rupert, Martin Weisel